Dermatologic Toxicities: A Chart Review of Clinical Management Among Patients With Metastatic Colorectal Cancer Treated With Panitumumab

Kimberly A. Lowe

Laura Sangaré

Kimberly A. Roehl

Scott Jung

George Kafatos

Tamer Garwin

anti-EGFR, panitumumab, acneform rash, metastatic colorectal cancer
CJON 2019, 23(2), 157-164. DOI: 10.1188/19.CJON.157-164

Background: At least 90% of patients with metastatic colorectal cancer (mCRC) who are treated with an anti-EGFR will develop a dermatologic toxicity. Preemptive management strategies have been shown to reduce the severity of rash.

Objectives: This article aims to describe treatment modalities used for the management of dermatologic toxicity among patients with mCRC who were treated with panitumumab and to assess the proportion of patients who were recommended preemptive versus reactive management strategies.

Methods: This retrospective chart review evaluated different treatment modalities and routes of administration. The modalities were categorized as prescription or over-the-counter. The timing in relation to the first dose of panitumumab was used to define preemptive versus reactive treatments.

Findings: In a sample of 330 patients, only 10% of patients were recommended to begin treatment for rash preemptively. The two most common treatment modalities for preemptively and reactively treated patients were prescription oral antibiotics and prescription topical antibiotics.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.